Eric J Topol

US Patent:

8133866, Mar 13, 2012

Filed:

Jun 7, 2010

Appl. No.:

12/802485

Inventors:

David M. Stern - Great Neck NY, US
Ann Marie Schmidt - Franklin Lakes NJ, US
Steven Marso - Shawnee KS, US
Eric Topol - Chagrin Falls OH, US
A. Michael Lincoff - Orange Village OH, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY
The Cleveland Clinic Foundation - Cleveland OH

International Classification:

C07K 19/00
C07K 14/00
A61K 39/395
A01N 25/00

US Classification:

514 165, 514 94, 4241341, 530350

Abstract:

This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject.

US Patent:

20060234245, Oct 19, 2006

Filed:

Aug 27, 2004

Appl. No.:

10/927747

Inventors:

Qing Wang - Shaker Heights OH, US
Eric Topol - Chagrin Falls OH, US
Lejin Wang - Cleveland OH, US
Chun Fan - Cleveland OH, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

A method of determining a person at risk of developing coronary artery disease includes detecting an alteration of at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor of the patient. The alteration substantially reduces the transcription activity of the resulting MEF2A transcription factor.

US Patent:

20080171701, Jul 17, 2008

Filed:

Aug 20, 2007

Appl. No.:

11/894809

Inventors:

David M. Stern - Great Neck NY, US
Ann Marie Schmidt - Franklin Lakes NJ, US
Steven Marso - Shawnee KS, US
Eric Topol - Chagrin Falls OH, US
A. Michael Lincoff - Orange Village OH, US

International Classification:

A61K 48/00
A61K 38/17
A61K 49/00

US Classification:

514 12, 514 44, 424 92

Abstract:

This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject.

US Patent:

20110294833, Dec 1, 2011

Filed:

May 27, 2010

Appl. No.:

12/789021

Inventors:

Eric Topol - La Jolla CA, US
Sarah Murray - Encinitas CA, US
Bradley Patay - San Diego CA, US

Assignee:

SCRIPPS HEALTH - La Jolla CA

International Classification:

A61K 31/519
A61P 25/28
A61P 9/00
A61P 19/10
A61P 27/00
A61P 3/10
A61P 3/04

US Classification:

5142621

Abstract:

Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans.

US Patent:

20130157347, Jun 20, 2013

Filed:

Jul 6, 2012

Appl. No.:

13/543661

Inventors:

Eric Topol - La Jolla CA, US
Samir Damani - San Diego CA, US
Mark Connelly - Doylestown PA, US
Galla Chandra Rao - Princeton Junction NJ, US

Assignee:

Veridex, LLC - Raritan NJ
Scripps Health - San Diego CA

International Classification:

C12Q 1/04

US Classification:

4352872, 4352887

Abstract:

Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).